Hyporesponsiveness to Darbepoetin Alfa in Patients With Heart Failure and Anemia in the RED-HF Study (Reduction of Events by Darbepoetin Alfa in Heart Failure): Clinical and Prognostic Associations [Short Communications]

Conclusions:
A poor response to darbepoetin alfa was associated with worse outcomes in heart failure patients with anemia. Patients with a poor response were difficult to identify using clinical and biochemical biomarkers.

Clinical Trial Registration:
URL: https://www.clinicaltrials.gov. Unique identifier: NCT00358215.

Source: Circulation: Heart Failure - January 24, 2018 Category: Cardiology Authors: van der Meer, P., Grote Beverborg, N., Pfeffer, M. A., Olson, K., Anand, I. S., Westenbrink, B. D., McMurray, J. J. V., Swedberg, K., Young, J. B., Solomon, S. D., van Veldhuisen, D. J. Tags: Clinical Studies, Heart Failure, Mortality/Survival Short Communications Source Type: research